List of Excipients in Branded Drug OXALIPLATIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Parenteral Medicines Inc	OXALIPLATIN	oxaliplatin	0703-3985	LACTOSE MONOHYDRATE
Teva Parenteral Medicines Inc	OXALIPLATIN	oxaliplatin	0703-3985	WATER
Winthrop US a business of sanofi-aventis US LLC	OXALIPLATIN	oxaliplatin	0955-1725	WATER
Winthrop US a business of sanofi-aventis US LLC	OXALIPLATIN	oxaliplatin	0955-1731	WATER

Generic Drugs Containing OXALIPLATIN

Company	Ingredient	NDC	Excipient
Sandoz Inc	oxaliplatin	0781-3315	WATER
Sandoz Inc	oxaliplatin	0781-9315	WATER
NorthStar RxLLC	oxaliplatin	16714-727	WATER
Accord Healthcare Inc	oxaliplatin	16729-332	WATER

What are the Most Frequently-Used Excipients in OXALIPLATIN?

# Of NDCs	Excipient
6	LACTOSE MONOHYDRATE
2	SODIUM HYDROXIDE
2	TARTARIC ACID
30	WATER

Oxaliplatin Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

Oxaliplatin is an off-patent platinum chemotherapy with a mature generic market and limited conventional exclusivity. Its commercial opportunity is concentrated in formulation engineering, supply reliability, ready-to-administer delivery, oncology workflow reduction, and differentiated combinations rather than in new composition-of-matter protection. The central excipient constraint is chloride incompatibility: oxaliplatin must be diluted in 5% dextrose injection, not sodium chloride-containing solutions.[1]

The strongest near-term opportunities are:

1. Ready-to-use oxaliplatin bags or dual-chamber systems.
2. Lower-waste, lower-volume vial presentations.
3. Improved stability after dilution.
4. Lyophilized or reconstitutable formulations with defensible intellectual property.
5. Specialty formulations that reduce preparation time and occupational exposure.
6. Regional manufacturing and supply contracts for generic oncology products.

What excipients are used in oxaliplatin injection?

The reference Eloxatin formulation contains oxaliplatin, lactose monohydrate and water for injection. Commercial presentations are supplied as a concentrated solution at 5 mg/mL in single-dose vials.[1]

Attribute	Reference oxaliplatin injection
Active ingredient	Oxaliplatin
Dosage form	Intravenous concentrate
Strength	5 mg/mL
Primary excipient	Lactose monohydrate
Diluent required for administration	5% dextrose injection
Chloride-containing diluents	Not compatible
Preservative	None in the reference formulation
Common vial sizes	50 mg and 100 mg
Administration route	Intravenous infusion
Typical colorectal cancer dose	85 mg/m² every two weeks in combination regimens

Lactose is used as a stabilizing excipient. The formulation does not rely on sodium chloride, phosphate buffers or other chloride-containing systems. The FDA label instructs healthcare professionals to dilute oxaliplatin in 250 to 500 mL of 5% dextrose injection and warns against the use of chloride-containing solutions.[1]

Why is chloride incompatibility the key formulation constraint?

Oxaliplatin is chemically sensitive to chloride. Chloride can promote conversion to reactive platinum-chloro species, changing the active drug profile and creating a formulation and administration risk.[2]

This restriction has commercial consequences:

• Oxaliplatin cannot use the hospital’s standard 0.9% sodium chloride workflow.
• Pharmacy staff must use dextrose-based diluents.
• Ready-to-use products must avoid chloride contamination throughout manufacturing, packaging and administration.
• Compatibility claims must cover infusion bags, tubing, filters and connectors.
• Manufacturing equipment cleaning validation must address residual chloride and other ionic contaminants.

The most defensible excipient strategy therefore begins with exclusion rather than addition. A formulation sponsor should control chloride sources in raw materials, process water, excipients, container closures and manufacturing equipment.

What formulation patents could protect oxaliplatin products?

The original oxaliplatin composition-of-matter protection has expired in major markets. New protection would need to come from a formulation, manufacturing process, delivery system or clinical use.

Potential claim categories include:

Patent category	Potential protected subject matter	Commercial value
Stabilized aqueous solution	pH control, impurity suppression, storage stability	Moderate
Lyophilized product	Cake structure, reconstitution time, residual moisture	Moderate to high
Ready-to-use infusion	Bag material, concentration, shelf life and administration compatibility	High
Dual-chamber container	Separation of oxaliplatin and diluent until use	High
Low-volume formulation	Higher concentration with acceptable stability and tolerability	Moderate
Packaging system	Light protection, oxygen control and low-extractables materials	Moderate
Manufacturing process	Chloride control, impurity profile and aseptic filling	Moderate
Combination product	Oxaliplatin with another active or supportive agent	High, if clinically meaningful
Method of use	New dosing sequence, biomarker or patient population	Potentially high

A formulation patent must claim more than the routine substitution of one pharmaceutically acceptable excipient for another. Patent strength improves when the formulation produces an unexpected result, such as a measurable reduction in degradation products, longer refrigerated stability, shorter reconstitution time or improved infusion compatibility.

How strong is the current oxaliplatin patent estate?

The basic oxaliplatin molecule is off patent. The commercial market is therefore primarily exposed to ANDA competition rather than biosimilar competition.

Composition-of-matter protection

Oxaliplatin was developed as a platinum complex distinct from cisplatin and carboplatin. The original compound and antitumor-use patents expired before the current generic market matured. The reference product received FDA approval in 2002, and generic oxaliplatin products entered the U.S. market after the principal exclusivity and patent barriers ended.[1][3]

Orange Book status

The FDA Orange Book is the controlling public source for current listed patents and regulatory exclusivity associated with approved U.S. drug products.[3] Oxaliplatin products should be evaluated by product and sponsor because listed patents can differ across reference and generic applications. The existence of an Orange Book listing does not itself establish that a patent will block launch; Paragraph IV litigation, settlements and court decisions determine practical launch risk.

Formulation and process patents

Later patents may still cover:

• Specific concentration ranges.
• Particular excipient ratios.
• Stabilized or lyophilized preparations.
• Infusion containers.
• Manufacturing conditions.
• New clinical uses or treatment sequences.

These patents generally create narrower barriers than composition-of-matter patents. They are most valuable when the product has a clear hospital purchasing advantage and the claim scope covers the finished commercial presentation.

When does oxaliplatin lose exclusivity?

Oxaliplatin lost its principal U.S. exclusivity and patent protection years ago. The reference product’s FDA approval date was August 9, 2002.[1] Standard small-molecule exclusivity periods, including five-year new chemical entity exclusivity and three-year clinical-investigation exclusivity where applicable, have expired.

The practical exclusivity timeline is:

Milestone	Timing or status
Original oxaliplatin development	1980s and 1990s
U.S. Eloxatin approval	August 9, 2002
Reference-product market protection	Expired
Generic oxaliplatin entry	Established
Current market structure	Multiple generic suppliers
Biosimilar pathway	Not applicable
New formulation exclusivity	Available only through a qualifying new product or patent

Unlike biologics, oxaliplatin does not receive a biosimilar reference-product framework. Generic applicants generally use the ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence rather than biosimilarity.[4]

Which companies are challenging oxaliplatin exclusivity?

The market has already moved beyond the principal challenge phase. Generic injectable manufacturers, including major U.S. and international generic suppliers, compete on price, supply continuity, vial sizes and hospital contracting.

Relevant competitor types include:

• Large generic injectables companies.
• Oncology-focused manufacturers.
• Contract manufacturers with sterile-filling capacity.
• Regional suppliers serving public hospitals.
• Specialty distributors with shortage-management capabilities.

The competitive barrier is not active-ingredient discovery. It is sterile manufacturing, validated aseptic processing, regulatory compliance, raw-material control and reliable supply.

What Paragraph IV challenges affect oxaliplatin?

Paragraph IV certification is primarily relevant when an ANDA applicant seeks approval before expiration of an Orange Book-listed patent. Because the foundational oxaliplatin patents have expired, current entry risk is more likely to involve:

• A new formulation patent.
• A newly listed method-of-use patent.
• A patent covering a specific delivery system.
• A patent dispute involving a differentiated oxaliplatin product rather than conventional generic concentrate.

A Paragraph IV challenge to a narrow formulation patent may not threaten the entire oxaliplatin market. It may affect only one ready-to-use presentation or one labeled use. The commercial question is whether the disputed patent covers the product that hospitals actually purchase.

What FDA regulatory status applies to oxaliplatin products?

Oxaliplatin is an FDA-approved prescription oncology drug administered intravenously. Conventional generic versions use the ANDA pathway. The product is subject to FDA requirements covering:

• Sterility and particulate control.
• Assay and degradation products.
• Container-closure integrity.
• Extractables and leachables.
• Stability under labeled storage conditions.
• Infusion compatibility.
• Aseptic process validation.
• Occupational handling of hazardous drugs.

The FDA label identifies oxaliplatin as a hazardous antineoplastic agent and describes warnings including peripheral sensory neuropathy, hypersensitivity reactions, myelosuppression, pulmonary toxicity and hepatotoxicity.[1]

A new excipient system can trigger additional regulatory scrutiny when it changes exposure, stability, toxicity, administration time or compatibility. For an ANDA, the formulation should remain as close as possible to the reference product unless the proposed difference is clinically justified and supported by the applicable FDA pathway.

What excipient strategies offer the best commercial opportunity?

Ready-to-use oxaliplatin infusion bags

A ready-to-use product could remove pharmacy dilution steps and reduce preparation errors. The formulation would need a validated shelf life in a compatible bag, dependable stability at the marketed concentration and evidence that the container does not introduce chloride or reactive contaminants.

The commercial advantage is operational. Hospitals may pay a premium for lower preparation labor, reduced hazardous-drug compounding and lower waste.

Higher-concentration products

A higher-concentration formulation could reduce infusion volume and packaging size. This approach faces technical limits:

• Greater concentration can accelerate degradation or precipitation.
• Infusion tolerability must remain acceptable.
• Dose calculations vary by body-surface area.
• The product must maintain uniformity across vial withdrawals.
• Safety data may be needed if administration practices change.

A higher-concentration product has greater value in outpatient oncology centers where chair time and pharmacy throughput are constrained.

Lyophilized oxaliplatin

A lyophilized product may improve long-term stability and reduce dependence on a liquid formulation. Its commercial value depends on whether the final product offers a meaningful improvement over existing liquid concentrates.

Potential advantages include:

• Longer room-temperature stability.
• Reduced sensitivity to transportation conditions.
• Lower degradation during storage.
• Flexible global distribution.

The disadvantages are reconstitution time, operator steps and the need to prove that the reconstituted solution has the same quality and compatibility profile as the reference product.

Dual-chamber systems

A dual-chamber vial or bag can separate oxaliplatin from its diluent until administration. This design could improve stability while delivering a ready-to-use product after activation.

The principal intellectual-property opportunity is the combined system: drug formulation, chamber architecture, activation mechanism, materials and administration instructions. The system must remain intuitive for oncology pharmacy staff and compatible with existing infusion pumps.

Low-waste vial configurations

Oxaliplatin dosing is based on body-surface area, so many patients receive doses that do not match available vial sizes. Smaller vial sizes, larger multi-dose-free presentations or optimized packaging could reduce discarded drug.

The commercial case is strongest where institutions measure hazardous-drug waste, pharmacy labor and drug acquisition cost together.

How does oxaliplatin compare with competing platinum drugs?

Drug	Main formulation issue	Generic or biosimilar status	Excipient opportunity
Oxaliplatin	Chloride incompatibility; neuropathy-focused clinical use	Generic small molecule	Ready-to-use dextrose-based products and stability
Cisplatin	Concentration, hydration and renal toxicity management	Generic small molecule	Premixes, storage stability and dose-convenient bags
Carboplatin	Concentration and solution stability	Generic small molecule	Premixes, low-waste packaging and outpatient delivery
Liposomal platinum candidates	Complex carrier and release control	Product-specific	Higher-value delivery and toxicity differentiation

Oxaliplatin has a stronger excipient differentiation opportunity than a basic vial-to-vial generic because its chloride restriction creates a distinct hospital workflow. Cisplatin and carboplatin also support premix and ready-to-use opportunities, but their formulation and clinical constraints differ.

What manufacturing and intellectual-property barriers remain?

The most material barriers are technical and operational:

1. Sterile manufacturing capacity.
2. Control of chloride and other ionic impurities.
3. Container compatibility with dextrose-based solutions.
4. Stability-indicating analytical methods.
5. Control of platinum-related degradation products.
6. Hazardous-drug worker protection.
7. Reliable access to oxaliplatin active pharmaceutical ingredient.
8. Scale-up without changing impurity profiles.
9. Global registration of different presentations.
10. Supply continuity during oncology shortages.

Manufacturing-process patents can support differentiation, but regulatory approval and purchasing contracts often provide more immediate commercial value than narrow patent claims. A sponsor should seek claims covering the complete product system and validate them with comparative stability and workflow data.

What licensing deals and partnering opportunities exist?

The most credible partnering opportunities are now formulation and manufacturing transactions rather than licenses to the oxaliplatin molecule.

Potential deal structures include:

• Licensing a ready-to-use infusion platform to a generic injectable company.
• Contract manufacturing for regional oncology suppliers.
• Co-development with a hospital pharmacy automation company.
• Licensing a dual-chamber container from a device manufacturer.
• Supplying a differentiated product to group purchasing organizations.
• Acquiring a formulation patent family with international rights.
• Developing a private-label oncology portfolio around oxaliplatin, cisplatin and carboplatin.

The historical commercial model for oxaliplatin involved collaboration between its developer, Debiopharm, and larger pharmaceutical commercialization partners. Current value is more likely to arise from product execution, geographic registration and manufacturing scale than from legacy molecule rights.[5]

What generic launch risks exist?

A conventional generic oxaliplatin launch faces low patent risk but meaningful execution risk. The principal risks are:

• Price erosion from multiple suppliers.
• FDA inspection findings.
• Sterile manufacturing interruptions.
• Shortages of active ingredient or critical packaging.
• Product recalls related to particulates or container integrity.
• Failure to demonstrate formulation equivalence.
• Hospital reluctance to switch from established suppliers.
• Low margins after contract rebidding.

A differentiated product can reduce price exposure if it demonstrates a measurable operational benefit. A ready-to-use product, for example, may compete on total treatment cost rather than vial acquisition price.

What is the commercial outlook for oxaliplatin excipients?

The excipient market opportunity is not a large-volume opportunity based on excipient sales alone. The more attractive model is value capture through a finished dosage form.

High-potential targets include:

• Dextrose-compatible stabilizer systems.
• Low-extractables bag materials.
• Lyophilization protectants.
• Reconstitution aids.
• Oxygen-control packaging.
• Chloride-free process systems.
• Ready-to-use infusion platforms.
• Pharmacy automation-compatible containers.

The strongest product should combine a formulation benefit with a procurement benefit. Stability alone may not justify premium pricing in a mature generic market. Stability plus lower pharmacy labor, less waste or reduced preparation risk is more commercially defensible.

Key Takeaways

• Oxaliplatin is an off-patent small molecule with established generic competition.
• The reference injection uses lactose monohydrate and water for injection at 5 mg/mL.
• Chloride incompatibility is the central excipient and administration constraint.
• Biosimilar risk does not apply because oxaliplatin is a chemically synthesized small molecule.
• New commercial value depends on formulation, packaging, manufacturing and workflow differentiation.
• Ready-to-use bags, dual-chamber systems, lyophilized products and low-waste vial sizes are the leading opportunities.
• Formulation patents must claim a specific technical solution and preferably demonstrate an unexpected stability or operational result.
• Manufacturing reliability and FDA-compliant sterile production are more important barriers than legacy molecule patents.
• Licensing opportunities are strongest in finished products, delivery systems and regional manufacturing.
• The most defensible premium position is a product that reduces total oncology pharmacy cost, not merely a product with a different excipient.

FAQs

Can sodium chloride be used to dilute oxaliplatin?

No. The FDA label directs dilution in 5% dextrose injection and warns against chloride-containing solutions because of incompatibility.[1]

Is oxaliplatin a biosimilar product?

No. Oxaliplatin is a small-molecule platinum complex. Competing products generally use the ANDA generic-drug pathway rather than the biosimilar pathway.

Can lactose be replaced in an oxaliplatin formulation?

Yes, a sponsor may develop an alternative excipient system, but the product must meet applicable quality, stability, compatibility and regulatory requirements. A replacement excipient may also create a new formulation patent opportunity if it produces a non-obvious technical benefit.

What is the strongest oxaliplatin formulation patent opportunity?

A ready-to-use or dual-chamber product with demonstrated long-term stability, chloride control, container compatibility and reduced pharmacy preparation is likely to have greater commercial value than a routine excipient substitution.

Does oxaliplatin still have meaningful patent protection?

The original molecule is off patent. Meaningful protection may still arise for new formulations, delivery systems, manufacturing processes or narrowly defined methods of use, subject to the current FDA Orange Book and applicable national patent registers.

References

1. U.S. Food and Drug Administration. (2023). Eloxatin (oxaliplatin) injection prescribing information. https://www.accessdata.fda.gov
2. Hall, M. D., Telma, K. K., Chang, K. E., & Storr, T. (2014). Chronic exposure to platinum compounds causes selective changes in NMR-visible metabolites in human cancer cells. Journal of Biological Inorganic Chemistry, 19(7), 945-955.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2018). ANDA submissions: Content and format guidance for industry. https://www.fda.gov
5. Debiopharm. (n.d.). Oxaliplatin and oncology product development history. https://www.debiopharm.com